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Abstract: The first hydroxilated series of coumarin-chalcone derivatives has been 
synthesize starting from the corresponding salicyl aldehyde and β-ketoester precursors 
by a Knoevenagel reaction in order to obtain the methoxy derivatives which have been 
further hydrolyzed with a Lewis acid. 





Coumarins and chalcone are a family of natural and synthetic compounds that 
have raised an enormous interest for a long time due to its biological applications. One 
of the biggest applications of coumarins resides on the wide range of pharmacological 
activities such as antimicrobial, antiviral, antioxidant, antiplatelet, vasorelaxant or 
enzymatic inhibitors1,2,3,4 so this coumarin scaffold give us a hint in the discovery and 
development of new drugs. Besides coumarins, chalcones share a wide range of this 
biological properties like antiproliferative, cardioprotector, or anti-inflammatory 
activity5,6,7 and in the present year chalcones have been proposed as valid scaffolds for 
monoamino oxidases inhibitors8.  
On the other hand, many studies suggest that polyphenols may be involved in 
neurotoxic or cyclooxygenase activity as well as they play a role as chemopreventive and 
tumor growth inhibition agents and their protective properties against oxidative 
stress.9,10,11 It is for these reasons that we have synthesized a novel series of 
hydroxylated coumarin-based compounds containing a chalcone moiety in order to 
make different biological essays and test their potential pharmacological activities. 
 
Results and Discussion 
 
 The aim of this work has been to synthesize new hydroxy coumarin-chalcone 
hybrids which contain the hydroxyl sustituents in the aromatic rings that can potentially 
be used as new lead compounds in drug discovery. 
 Compounds were synthesized using a two steps synthetic strategy that allows us 


























Figure 1. Synthetic route used to prepare hydroxy coumarin-chalcone hybrids. 
 
 The main scaffold with methoxy substituents was prepared by a Knoevenagel 
reaction in basic conditions in 82-93% yields. First synthesized derivatives have the 
methoxy sustituens placed in positions 8 and 4’, (Table 1) 
Table 1. Coumarin-chalcone hybrids 
 
Compound 1 2 3 4 







Hydroxy derivatives were further prepared from the ether precursors by catalysis 
with a Lewis acid, BBr3 in CH2Cl2
12
. Purification of compounds 1-2 was made by 
recristalization in MeOH, while compounds 3-4 were purified by flash chromatography. 
The followed methodologies to prepare compounds 1-2, in a parallel synthesis 
way, bring the opportunity of synthesize structural related compounds with punctual 
modifications in the aromatic rings depending on the starting materials. 
Biological assays as vasodilatators, antioxidants and monoaminooxidase 
inhibitors are currently being carried out and results will be further presented.  
 
General Experimental Procedure 
 
 All reactions were carried out under dry and deoxygenated argon atmosphere. 
Solvents were used as anhydrous by reflux of each solvent over an appropriate dryer 
agent and further distillate under argon atmosphere. 
 Qualitative identification of the compounds and course of the reactions were 
visualized using TLC plates (Merck, silica gel 60F254) under UV light (254-366 nm). 
Melting points were determined using a Reichert Kofler thermopan or in capillary tubes 
on a Büchi 510 apparatus and are uncorrected. 1H NMR spectra were recorded on a 
Bruker WM-250 at 250 MHz using TMS as internal standard (chemical shifts in δ 
values, J in Hz). 
General procedure for the preparation of 3-benzoylcoumarins: In a round 
bottom flask the appropiated salicylaldehyde (1 equiv.unless otherwise noted) and ethyl 
benzoylacetate (1 eq. unless otherwise indicated) were dissolved in dry EtOH. Were 
then added 5 drops of piperidine, and the reaction was subjected to reflux. The reaction 
was monitored by TLC and after the end of it, the solution was cooled on ice and the 
precipitate was filtered and washed with ether. The solid obtained was purified by 
recrystallization in MeOH: CH2Cl2 and / or column chromatography. 
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General procedure for the preparation of hydroxy 3-benzoylcoumarins: 
Ether derivatives of 3-benzoylcoumarins (1 eq.) were dissolved in dry DCM and BBr3 
(20 eq.) was added dropwise at room temperature in a sealed tube. Mixture was stired 
and heated at 80ºC for 48h. After cooling to room temperature, the crude reaction 
mixture was quenched carefully with ice, water and 1 N HCl. The aqueous layer was 
extracted with AcOEt (3 × 50 cm3) and the combined organic extracts were washed 
with saturated aqueous NaHCO3 and brine, dried (MgSO4) and concentrated to dryness. 
3-(p-methoxybenzoyl)coumarin (1): Yield: 93%. 1H-NMR (250 MHz, DMSO-d6) δ 
ppm 8.34 (s, 1H, H-4), 7.92 (d, J = 8.8 Hz, 2H, H-2’, H-6’), 7.83 (d, J = 8.6 Hz, 1H, H-
5), 7.70 (d, J = 7.26 Hz, 1H, H-8), 7.55-7.33 (m, 2H, H-6, H-7), 7.05 (d, J = 8.8 Hz, 
2H, H-3’, H-5’), 3.85 (s, 3H, -CH3). MS m/z (%):281 ([M+1]
+, 19), 280 ([M]+, 82), 135 
(100), 77 (20). 
3-benzoyl-5-bromo-8-methoxycoumarin (2): Yield: 82%. 1H-NMR (250 MHz, 
CDCl3) δ ppm 7.78 (s, 1H, H-4), 7.69 (d, J = 7.3, 2H, H-2’, H-6’), 7.51-7.24 (m, 3H, H-
3’, H-4’, H-5’), 7.14 (s, 1H, H-5), 7.09 (s, 1H, H-7), 3.82 (s, 3H, -CH3) MS m/z (%):360 
([M+1]+, 18), 359 ([M]+, 58), 358 (18), 357 (58), 105 (100), 77 (70). 
3-(p-hydroxybenzoyl)coumarin (3): Yield: 67%. 1H NMR: (250 MHz, DMSO-d6) δ 
ppm 10.6 (s, 1H, -OH), 8.3 (s, 1H, -H4), 7.8 (d, J =8.5 Hz, 4H, -H2’, -H3’, -H5’, -H6’), 
7.7 (t, J = 7.50 Hz, 1H, -H5), 7.5-7.3 (m, 2H, H6, H7), 6.9 (d, J =8.5 Hz, 1H, -H8). MS 
m/z 267 ([M+1]+, 12), 266 ([M]+, 57), 249 (22) 
3-benzoyl-5-bromo-8-hydroxycoumarin (4): Yield: 52%. 1H NMR: (250 MHz, 
DMSO-d6) δ ppm 10.8 (s, 1H, -OH), 7.8 (d, J =7.9 Hz, 2H, H2’, H6’) 7.6-7.3 (m, 3H, -
H3’, -H4’, -H5’), 7.0 (s, 1H, -H5), 6.8 (s, 1H, H7). MS m/z 346 ([M+1]+, 18), 345 
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